<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Third, mobilization efficacy might be different in German patients as compared to patients from other countries due to population characteristics and chemotherapy regimens. In a retrospective study conducted in Germany prior to the introduction of plerixafor, Wuchter et al found that NHL patients identified as poor mobilizers, all of those with CD34+ cell count between 11–19/µl (i.e., "borderline” poor mobilizers) collected sufficient hematopoietic stem cells (2.0 × 10
 <sup>6</sup> cells/kg). On the other hand, among patients with a CD34+ cell count between 6–10/µl and less than 5/µl only 65% and 35% achieved their collection target [
 <xref ref-type="bibr" rid="CR7">7</xref>].
</p>
